ArticleProceedings of the National Academy of Sciences of the United States of America2007
Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 76 citations in OpenAlex.
- Prediction of Rab5B inhibitors through integrative in silico techniques.Molecular diversity · 2024Article
- A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicronProtein & cell · 2023Article
- Structure-Based Molecular Networking for the Discovery of Anti-HBV Compounds fromMolecules (Basel, Switzerland) · 2022Article
- Plant-derived lignans as potential antiviral agents: a systematic review.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- Antiviral Activity of Cananga odorata Against Hepatitis B Virus.The Kobe journal of medical sciences · 2019Article
- Article
- Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.Antiviral research · 2018Review
- Structure-activity relationships of cryptopleurine analogs with E-ring modifications as anti-hepatitis C virus agents.Bioorganic & medicinal chemistry · 2018Article
- Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.Journal of natural medicines · 2016Article
- A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.Antimicrobial agents and chemotherapy · 2015Article
- Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.Viruses · 2015Review
- Potent natural products and herbal medicines for treating liver fibrosis.Chinese medicine · 2015Article
- Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening.Cell & bioscience · 2015Article
- Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.Acta pharmacologica Sinica · 2014Article
- Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4α in vitro and in vivo.The Journal of biological chemistry · 2012Article
- Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.European journal of medicinal chemistry · 2012Article
- Transforming growth factor-β1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4α expression.PloS one · 2012Article
- HBV life cycle and novel drug targets.Hepatology international · 2011Article
- Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.World journal of gastroenterology · 2011Article
- A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Helioxanthin is a natural product that inhibits the replication of a number of viruses. We found that a previously undescribed helioxanthin analogue, 8-1, exhibited potent anti-hepatitis B virus (HBV) activity with little cytotoxicity. 8-1 suppressed both HBV RNA and protein expression, as well as DNA replication of both wild-type and 3TC-resistant virus. Time-course analyses revealed that RNA expression was blocked first after treatment with 8-1, followed by viral proteins, and then DNA. 8-1 inhibited the activity of all HBV promoters by decreasing the binding of hepatocyte nuclear factor 4 (HNF-4), HNF-3, and fetoprotein factor to the precore/core promoter enhancer II region. The amount of HNF-4 and HNF-3 was decreased posttranscriptionally by 8-1 in HBV-producing cells, but not in HBV-negative cells. Therefore, 8-1 suppresses HBV replication by posttranscriptional down-regulation of critical transcription factors in HBV-producing cells, thus diminishing HBV promoter activity and blocking viral gene expression and replication. This mechanism is unique and different from other anti-HBV compounds previously described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.